Deltagen Inc. (DGEN) provides drug discovery tools and services to the biopharmaceutical industry; it offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, small-molecule and secreted protein drug targets, and target validation data in the areas of immunology and metabolic diseases. The company develops technology that converts raw data into mammalian gene function information to help pharmaceutical and biotechnology companies expedite the drug discovery process through advanced bioinformatics and novel gene target identification. Incorporated in 1999 and headquartered at 1900 South Norfolk Street, Suite 105, San Mateo, California, USA, Deltagen operates primarily in the life sciences tools and services segment of the pharmaceuticals and biotechnology sector, targeting biopharmaceutical firms with its specialized offerings.